

Long-Term Outcomes of Pediatric Graves Disease Patients Treated with Anti-Thyroid Drugs: Experience from a Taiwan Medical Center

Short title

Long-term outcomes in children and adolescents with Graves disease

Ya-Ting Chiang^{1,2¶}, Wei-Hsin Ting^{1,3,4¶}, Chi-Yu Huang^{1,3}, Shih-Kang Huang¹,

Chon-In Chan¹, Bi-Wen Cheng⁵, Chao-Hsu Lin⁵, Yi-Lei Wu⁶, Chen-Mei Hung⁷,

Hsin-Jung Li⁸, Chia-Jung Chan⁹, Yann-Jinn Lee^{1,3,10,11,12*}

¹Department of Pediatric Endocrinology, MacKay Children's Hospital, Taipei, Taiwan

²Department of Pediatric Endocrinology, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi, Taiwan

³Department of Medicine, MacKay Medical College, New Taipei City, Taiwan

⁴ MacKay Junior college of Medicine, Nursing and Management, New Taipei City, Taiwan

⁵ Department of Pediatrics, MacKay Memorial Hospital HsinChu, Hsin-Chu, Taiwan

⁶ Department of Pediatrics, Changhua Christian Hospital, Chang-Hua, Taiwan

⁷ Department of Pediatrics, Hsinchu Cathay General Hospital, Hsin-Chu, Taiwan

⁸ Department of Pediatrics, St. Martin De Porres Hospital, Chiayi, Taiwan

⁹ Chiahung Clinic, Taichung, Taiwan

¹⁰ Department of Medical Research, MacKay Memorial Hospital Tamsui, New Taipei City, Taiwan

¹¹ Department of Pediatrics, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan

¹²Institute of Biomedical Sciences, MacKay Medical College, New Taipei City, Taiwan

*Corresponding author

E-mail: yannlee@mmh.org.tw (Lee YJ)

¶ These authors contributed equally to this work

1 **Abstract**

2 Graves disease (GD) is the most common cause of thyrotoxicosis in children and
3 adolescents, accounting for 15% of all thyroid diseases during childhood.
4 Anti-thyroid drugs (ATD) are recommended as the first-line treatment in children and
5 adolescents. However, the remission rate is lower in children than in adults, and the
6 optimal treatment duration and favorite factors associated with remission remain
7 unknown. We aimed to investigate long-term outcomes of pediatric GD patients
8 receiving ATD. We retrospectively reviewed medical charts of 300 pediatric GD
9 subjects, who were initially treated with ATD and followed up for more than one year,
10 from 1985 to 2017 at MacKay Children's Hospital. The 300 patients comprised 257
11 (85.7%) females and 43 (14.3%) males, median age at diagnosis was 11.6 (range
12 2.7-17.8) years, and median follow-up period was 4.7 (range 1.1-23.9) years. Overall,
13 122 patients achieved the criteria for discontinuing ATD treatment, seventy-nine
14 (39.9%) patients achieved remission, with a median follow-up period of 5.3 (range
15 1.5-20.1) years. Patients in the remission group were more likely to be aged < 5 years
16 (remission vs. relapse vs. ongoing ATD; 11.4 vs. 0 vs. 2.6%, $P=0.02$), less likely to
17 have a family history of thyroid disease (24.1 vs. 42.1 vs. 52.6 %, $P=0.001$), and had

- 18 lower TRAb levels (42.8 vs. 53.6 vs. 65.1 %, $P=0.02$). *Conclusion:* Long-term ATD
- 19 remains an effective treatment option for GD in children and adolescents. Pediatric
- 20 GD patients aged < 5 years, having no family history of thyroid disease and having
- 21 lower TRAb levels were more likely to achieve remission.

22 **Introduction**

23 Graves disease (GD) is a common disorder in adults, with a prevalence of
24 approximately 0.5-1%. Pediatric patients account for < 5% of the total number of GD
25 patients [1]. However, GD remains the most frequent cause of thyrotoxicosis in
26 children and adolescents, accounting for 15% of thyroid disease during childhood [2].
27 The incidence increases gradually from young children and peaks in adolescents [3].
28 The optimal treatment option for GD in children and adolescents remains
29 controversial. Current treatment approaches for GD include anti-thyroid drugs (ATD),
30 radioactive iodine and surgery. ATD is usually recommended as the first-line
31 treatment for GD in children and adolescents. However, the remission rate is lower in
32 children than in adults [2, 4, 5]; the optimal treatment duration and the favorite factors
33 associated with remission have not yet been established in children and adolescents
34 [6-8].

35 The issue of how long ATD should be used in pediatric GD is important and
36 warrants further study [5, 9]. In adult GD patients, if remission does not occur after
37 12-18 months of ATD therapy, the chance of remission with prolonged therapy is
38 very low [4, 10]. In the pediatric population, longer treatment duration is associated

39 with a higher remission rate. Lipple reported that the median time to remission with
40 ATD was 4.3 years, and the expected remission rate was 25% every 2 years [11].
41 Leger reported that overall estimated remission rates after withdrawing ATD
42 increased with time and were 20, 37, 45, and 49% after 4, 6, 8, and 10 years follow-up,
43 respectively [6]. A retrospective study in Japan revealed that the remission rate was
44 46.2% after a median duration of 3.8 years [12]. However, long-term remission rate of
45 pediatric GD cases treated with ATD was very low (< 20%), in cohorts from Australia
46 [13] and Denmark [14].

47 Pediatric GD patients with some clinical or laboratory characteristics may have a
48 higher chance of remission. A prospective study in France revealed that younger (age
49 < 5 years), non-Caucasian children with severe initial presentation had a higher
50 chance of relapse and required longer ATD treatment [7]. Another prospective study
51 reported that initial less severe hyperthyroidism and the presence of other
52 autoimmune conditions were remission predictors [6]. A similar study in the USA
53 demonstrated that lower total T3, euthyroidism within 3 months of PTU and older age
54 (age > 14.6 years) were significant remission predictors [8]; however, the largest
55 retrospective study to date did not identify any significant factors to predict remission

56 [12]. These above studies showed no consistent findings and few studies were
57 conducted in the Asian population.

58 We aimed to investigate the long-term outcomes of pediatric GD patients who
59 received ATD and identify probable clinical or laboratory factors associated with
60 remission. We documented our 32-year experience in 300 children and adolescents
61 with GD. Patients were classified as remission, relapse, and ongoing ATD groups;
62 clinical and laboratory characteristics were presented and analyzed.

63 **Material and methods**

64 We retrospectively reviewed medical charts of 396 GD subjects from 1985 to 2017 at
65 MacKay Children's Hospital. All the patients were diagnosed before 18 years of age.
66 GD was diagnosed based on clinical and laboratory evidence, including thyrotoxicosis,
67 diffuse goiter, with or without ophthalmopathy, elevated free T4/total T4 and
68 suppressed TSH levels, and presence of autoantibodies against TSH receptor [4, 15].
69 Seventy-one patients were followed for less than one year, 6 patients received
70 radioactive therapy and 19 patients received surgery as definite therapy and thus were
71 excluded from our analyses. The remaining 300 patients initially treated with ATD
72 and followed up for > 1 year constituted our study population.

73 We collected the following information from patients' medical charts: age at
74 diagnosis, sex, height, weight, body mass index (BMI), pubertal status, family history
75 of thyroid disease (including autoimmune thyroid disease, goiter, thyroid nodule and
76 thyroid cancer) in third-degree relatives, personal history of other autoimmune disease
77 (type 1 diabetes, myasthenia gravis) or other syndrome (Down syndrome), initial free
78 T4 (fT4), TSH receptor antibody (TRAb) levels, and interval until fT4, TRAb level
79 normalized. All patients were initially treated with carbimazole or methimazole, with

80 a starting dose between 2.5 and 30 mg/day, (0.05-0.80 mg/kg/day) depending on the
81 patients' age, body weight, clinical severity, and initial fT4 levels. PTU was only used
82 when the patients could not tolerate the side effect of carbimazole or methimazole.
83 The dose was subsequently titrated and adjusted to maintain euthyroidism. Patients
84 were initially followed at 2-4 weeks interval and then every 3 months after thyroid
85 function test results normalized. ATD was discontinued if euthyroidism was
86 maintained at a low dose (methimazole \leq 2.5 mg/day) for more than 6-12 months, and
87 the TRAb was near or within the normal range. Remission was defined as the
88 maintenance of euthyroidism \geq 12 months after ATD was discontinued and no
89 recurrence of thyrotoxicosis was recorded during the follow-up period. Relapse was
90 defined as an elevated fT4, suppressed TSH levels together with restarting ATD use.

91 We obtained informed written consent from the parents or guardians of the
92 children, and the study was approved by Mackay Memorial Hospital institutional
93 review board (18MMHIS156e).

94 **Statistical analysis**

95 We preformed descriptive statistics with categorical variables expressed as
96 percentages and continuous variables as medians (25-75 percentiles) or means \pm SD.

97 *Univariate analysis.* A comparison of frequencies was performed employing the
98 chi-square test or Fisher's exact test (in case of expected frequencies < 5). A
99 comparison of continuous variables was carried out using One-way ANNOVA or
100 Kruskal-Wallis test while multiple groups were compared.

101 **Multivariate analysis.** Multivariate logistic regression model was used to identify the
102 possible remission predictors. Variables that were associated with remission in the
103 univariate analysis and those judged to be potentially clinically relevant were entered
104 the model. The variables used in the analysis were the proportion of young patients
105 (age < 5 years), the proportion of patients with negative family history, initial FT4
106 levels, and TRAb levels at diagnosis. All the statistical analyses were performed using
107 SAS software (version 9.4).

108 **Results**

109 The 300 patients comprised 257 (85.7%) females and 43 (14.3%) males. Their median
110 age at diagnosis was 11.6 (range 2.7-17.8), and 11 patients (3.7%) were diagnosed
111 before the 5 years of age. The age and sex distributions were shown in Fig 1. One
112 hundred and twelve patients (37.3%) reported a family history of thyroid disease. The
113 median follow-up period of these patients was 4.7 (range 1.1-23.9) years. There were
114 102 patients (34%) who were lost follow-up during the study period. Those who were
115 lost follow-up had no significant differences in the clinical and laboratory
116 characteristics compared with those who remained in the study, except for shorter
117 follow-up period (3.7 vs. 5.3 years, $P=0.004$).

118

119 **Fig 1. Age and sex distribution of children and adolescents with Graves disease**
120 **(GD) diagnosis.**

121 The 300 patients consisted of 257 females and 43 males. The median age at diagnosis
122 was 11.6 years (range 2.7–17.8 years). The incidence of GD increased markedly
123 during adolescence.

124

125 From 198 patients who continued ATD treatment, ATD treatment was
126 subsequently ongoing in 76 (38.4%) and was categorized as ongoing ATD treatment
127 group. ATD was discontinued in 122 (61.6%) patients who met the criteria for
128 discontinuing ATD treatment. Seventy-nine (39.9%) patients met the remission
129 criteria, with a median follow-up of 5.3 (range 1.5-20.1) years and were classified as
130 the remission group. Thirty-eight (19.2%) patients relapsed after ATD was
131 discontinued, with a median of 0.7 (range 0.08-5.2) years and were assigned to the
132 relapse group. The clinical course of the study population was shown in Fig 2.

133

134 **Fig 2. Clinical course of the study population initially treated with anti-thyroid**
135 **drug (ATD).**

136 Of the 396 GD patients, 71 were followed for <1 year, 25 received definite therapy,
137 and were excluded from our analyses. Of the remaining 300 patients, 102 patients
138 were lost to follow-up during the study period. Of the 198 who continued ATD
139 treatment, ATD treatment was subsequently ongoing in 76 (38.4%) and was
140 discontinued in 122 (61.6%) patients who met the criteria of discontinuing ATD. Of
141 the 122 patients who discontinued ATD treatment, 79 (39.9%) achieved a remission,

142 38 (19.2%) experienced a relapse, and 5 (2.5%) were lost to follow-up.

143

144 Patients in the remission group were more likely to be aged < 5 years (remission
145 vs. relapse vs. ongoing ATD; 11.4 vs. 0 vs. 2.6%, $P=0.02$), less likely to have a
146 family history of thyroid disease (24.1 vs. 42.1 vs. 52.6%, $P=0.001$), and had lower
147 TRAb levels (42.8 vs. 53.6 vs. 65.1 %, $P=0.02$), (Table 1). In the remission group,
148 patients aged < 5 years tended to receive ATD for a longer period than those with
149 older age (younger vs. older age group: 7.2 vs. 5.0 years, $P=0.28$). The other variables,
150 including male proportion, the proportion of puberty, height, weight and BMI z score,
151 the proportion of patients with other diseases, initial ATD dose, initial serum fT4, and
152 the interval until fT4 and TRAb levels became normal did not show any significant
153 differences across the three groups.

154 **Table 1.** Clinical and Biochemical Characteristics of Four Groups: Remission Group, Relapse Group, and Ongoing Anti-Thyroid Drug
 155 Treatment Group

parameters	N	Remission Group, N = 79	Relapse group, N = 38	Ongoing ATD treatment group, N = 76	P-value
Age at diagnosis (years)	193	11.7 (8.5-13.6)	11.0 (9.1-15.2)	12.1 (10.3-15.1)	0.11
Age < 5 years, %	193	11.4	0	2.6	0.02*
Sex, % male	193	13.9	13.2	11.8	0.93
% puberty	284	67.5	66.7	81.1	0.12
*Height SDS at diagnosis	165	0.50 (-0.10-1.10)	0.40 (-0.45-1.15)	0.60 (0-1.40)	0.59
*Weight SDS at diagnosis	166	-0.40 (-0.90-0.10)	-0.40 (-0.90-0.40)	-0.20 (-0.90-0.20)	0.79
*BMI SDS at diagnosis	165	-0.80 (-1.20, -0.10)	-0.75 (-1.15, -0.10)	-0.70 (-1.00-0)	0.73
Family history of thyroid disease, %	193	24.1	42.1	52.6	0.001*
Other disease, %	193	21.5	10.5	14.5	0.27
Initial ATD dose (mg/kg/day)	191	0.41 (0.28-0.50)	0.35 (0.25-0.50)	0.36 (0.24-0.46)	0.18
Initial fT4 (ng/dL)	169	4.23 (3.14-5.58)	4.11 (3.14-5.50)	4.40 (3.37-5.07)	0.91
Initial TRAb, %	164	42.8 (29.2-72.8)	53.6 (30.6-72.6)	65.1 (47.2-77.7)	0.02*
fT4 at end of ATD Tx	113	1.37 (1.17-1.60)	1.39 (1.22-1.53)	NA	0.88
TRAb at end of ATD Tx	103	7.13 (0.84-9.81)	6.57 (3.14-9.28)	NA	0.40
Time until fT4 became normal (months)	193	5.0 (2.2-8.7)	3.5 (1.9-4.7)	3.4 (1.9-6.9)	0.13

Time until TRAb became normal (months)	141	31.4 (17.0-60.5)	25.8(14.4-34.3)	24.2 (13.3-35.3)	0.05
Duration of ATD Rx (years)	183	5.30 (2.90-8.60)	7.00 (5.60-8.20)	4.1 (2.40-6.00)	0.0001

156 Data were Median (25-75 percentile) in continuous variables or percentage in category variables

157 *One-way ANNOVA; Other variables: Kruskal-Wallis Test

158 In the multivariate logistic regression model, we further identified patients who
159 were aged < 5 years (Odds ratio [OR]: 12.6, 95% confidence interval [CI], 2.19-72.6;
160 $P = 0.005$), had no family history of thyroid disease (OR: 3.75, 95% CI, 1.80-7.81; P
161 = 0.0004), and had a lower initial TRAb levels (OR: 0.98, 95% CI, 0.97-0.99; $P =$
162 0.01) as remission predictors in pediatric GD (Table 2).

163 **Table 2.** Factors associated with remission in child and adolescents with Graves disease, multiple logistic regression model

Variable	Univariate analysis		Multivariate analysis	
	Odds ratio (95% CI)	P value	Odds ratio (95% CI)	P value
Age < 5 years	7.20 (1.51-34.3)	0.01	12.6 (2.19-72.6)	0.005
No family history of thyroid disease	3.05 (1.62-5.74)	0.001	3.75 (1.80-7.81)	0.0004
Initial TRAb, %	0.98 (0.97-0.997)	0.01	0.98 (0.97-0.99)	0.01

165 **Discussion**

166 In this study, we demonstrated that patients who aged < 5 years, who had no
167 family history of thyroid disease and who had lower TRAb levels were more likely to
168 achieve remission. There were 34% patients who were lost follow-up during the study
169 period. Among patients who continued the ATD treatment, the long-term remission
170 rate in pediatric GD patients was 39.9% after a median of 5.3 years of ATD treatment.

171 Our results suggested that GD patients who aged < 5 years had a higher chance
172 to achieve remission and tended to receive ATD for a longer course. These young
173 children were assumed to have better medical adherence under caregivers'
174 surveillance. Previous studies reported that pre-pubertal children needed a longer
175 medical treatment and had a lower remission rate than pubertal children [16]. Lazar et
176 al. reported that the remission rate was not different between pre-pubertal children and
177 adolescents, but the time to remission tended to be longer in pre-pubertal children [17].
178 Two prospective studies showed that younger GD patients were less likely to achieve
179 remission [8] or more likely to relapse after discontinuing ATD [7]. However, other
180 retrospective studies performed in Japan [12] and Taiwan [18] did not determine age
181 as a remission predictor. Because GD is rare in pre-pubertal children, especially in
182 those aged < 5 years, further studies are needed to clarify the relationship between
183 onset age and remission rate.

184 Our study showed that nearly 40% of pediatric GD patients had a family history
185 of thyroid disease, consistent with previous studies in the literature [6, 7, 12, 19]. Our
186 study also revealed that GD patients with a positive family history of thyroid disease
187 were less likely to achieve remission. A similar study performed in 194 adult GD
188 patients also proved that GD patients with a family history of thyroid disorders were

189 2.5 times more likely not to response to ATD treatment [20]. Although not all studies
190 demonstrated a significant association between thyroid disease family history and the
191 chance of remission [7, 8, 12, 21], our study still implied that family history acts as a
192 remission indicator at the time of GD diagnosis.

193 Consistent with previous reports, our study also demonstrated that GD patients
194 with lower titers of TRAb at diagnosis had a higher chance to remission [7, 21, 22].
195 TRAb was reported to be well correlated with GD severity and extra-thyroidal
196 manifestations [23], showing concomitancy with the clinical course and being
197 valuable for the diagnosis and management of children with GD [24]. A retrospective
198 study conducted in 115 children aged 3-15 years showed that a TRAb level ≤ 2.5
199 times the upper reference limit, TRAb normalization during ATD and TRAb
200 normalization time may predict further euthyroidism or hypothyroidism after ATD
201 treatment stopped [21]. Pediatric GD patients with non-Caucasian origins, higher
202 TRAb levels, higher free T4 levels, and younger age at diagnosis were reported to
203 have a higher relapse rate [7]. These above studies, combined with our findings,
204 confirmed TRAb as an indicator of GD activity and the predictive role for future
205 remission occurrence after medical therapy.

206 Contradictory to adult GD cases, while a fixed course of ATD (no longer than 18
207 months) was recommended [25, 26], most studies showed that a longer ATD
208 treatment duration increased remission rates in pediatric GD [2, 6, 7]. Recent
209 published guidelines therefore suggested a prolonged course of ATD therapy before
210 proceeding to definite therapy [26, 27]. However, the median time to remission
211 reported in the literature was highly variable, and the optimal duration of ATD has not
212 yet been determined. Our treatment protocol resulted in 40% of remission which is
213 consisted with previous studies [12, 28], after a median of 5.3 years of ATD treatment.

214 As shown in our study, long-term medical therapy resulted in high rates of lost follow
215 up. Some clinicians believe that hypothyroidism is preferable to hyperthyroidism,
216 because it is easier to treat and has a less serious morbidity [29]. However, medical
217 adherence is problematic not only for long-term ATD therapy but also for the
218 thyroxine supplement after hypothyroidism induced by definite therapy [30, 31].
219 Further long-term, prospective studies are required to determine the optimal duration
220 of ATD treatment for pediatric GD.

221 There were several limitations in our study. The first limitation came from its
222 retrospective nature, and high rates of lost follow up, which highlighted the
223 difficulties in the daily practice. Since pediatric GD patients need a protracted ATD
224 course to attain remission, meticulous and realistic counseling of patients and families
225 should be started from the time of diagnosis [31]. Second, we did not analyze the
226 patients' characteristics who receiving radioactive iodine and total thyroidectomy,
227 because few patients chose definite therapy in our institute, even in the relapse group.
228 Third, the documentation of a family history of thyroid disease is not limited to
229 autoimmune thyroid disease, which might introduce some bias to our estimate. Finally,
230 the definition of remission is euthyroidism for only 12 months after ATD is
231 discontinued. It is possible that patients experienced relapse one year after
232 discontinuing medication. However, previous studies indicated that the risk of relapse
233 declines with times [7, 12].

234 In conclusion, we identified pediatric GD patients who aged < 5 years, had no
235 family history of thyroid disease and had lower TRAb levels were more likely to
236 achieve remission. These remission predictors helped us to discuss with patients and
237 families in the process of shared decision making and treatment plan. Long-term ATD
238 is still a treatment option for pediatric GD, because our study showed that it resulted

239 in a remission rate of 40%, with a median of 5.3 years ATD course. Such a long-term
240 treatment course was inevitably associated with a poor medical adherence, realistic
241 discussion and consultation should be applied in every newly diagnosed pediatric GD
242 patients.

243

244 **Acknowledgments**

245 This study was supported by grants RD1050151 from Mackay Medical College; and
246 MMH 108-119 and MMH E-108-7 from MacKay Memorial Hospital, Taipei,
247 Taiwan.

248 **References**

- 249 1. Abraham-Nordling M, Bystrom K, Topping O, Lantz M, Berg G, Calissendorff J,
250 et al. Incidence of hyperthyroidism in Sweden. *Eur J Endocrinol.*
251 2011;165(6):899-905. doi: 10.1530/EJE-11-0548. PubMed PMID: 21908653.
- 252 2. Leger J, Kaguelidou F, Alberti C, Carel JC. Graves' disease in children. *Best Pract*
253 *Res Clin Endocrinol Metab.* 2014;28(2):233-43. doi: 10.1016/j.beem.2013.08.008.
254 PubMed PMID: 24629864.
- 255 3. Lavard L, Ranlov I, Perrild H, Andersen O, Jacobsen BB. Incidence of juvenile
256 thyrotoxicosis in Denmark, 1982-1988. A nationwide study. *Eur J Endocrinol.*
257 1994;130(6):565-8. PubMed PMID: 8205255.
- 258 4. DAVIES TF, LAURBERG P, BAHN RS. Hyperthyroid disorders. In: Melmed S,
259 MBChB, MACP; , Polonsky KS, MD; , Larsen PR, MD, FRCP; , Kronenberg HM,
260 MD, editors. *Williams Textbook of Endocrinology, Thirteenth Edition.*
261 Philadelphia, PA 19103-2899: Elsevier; 2016. p. 369-415.
- 262 5. Kaguelidou F, Carel JC, Leger J. Graves' disease in childhood: advances in
263 management with antithyroid drug therapy. *Horm Res.* 2009;71(6):310-7. doi:
264 10.1159/000223414. PubMed PMID: 19506387.
- 265 6. Leger J, Gelwane G, Kaguelidou F, Benmerad M, Alberti C, French Childhood
266 Graves' Disease Study G. Positive impact of long-term antithyroid drug treatment
267 on the outcome of children with Graves' disease: national long-term cohort study.
268 *J Clin Endocrinol Metab.* 2012;97(1):110-9. doi: 10.1210/jc.2011-1944. PubMed
269 PMID: 22031519.
- 270 7. Kaguelidou F, Alberti C, Castanet M, Guitteny MA, Czernichow P, Leger J, et al.
271 Predictors of autoimmune hyperthyroidism relapse in children after

- 272 discontinuation of antithyroid drug treatment. *J Clin Endocrinol Metab.*
273 2008;93(10):3817-26. doi: 10.1210/jc.2008-0842. PubMed PMID: 18628515.
- 274 8. Glaser NS, Styne DM, Organization of Pediatric Endocrinologists of Northern
275 California Collaborative Graves' Disease Study G. Predicting the likelihood of
276 remission in children with Graves' disease: a prospective, multicenter study.
277 *Pediatrics.* 2008;121(3):e481-8. doi: 10.1542/peds.2007-1535. PubMed PMID:
278 18267979.
- 279 9. Rivkees SA. Pediatric Graves' disease: controversies in management. *Horm Res*
280 *Paediatr.* 2010;74(5):305-11. doi: 10.1159/000320028. PubMed PMID: 20924158.
- 281 10. Weetman AP. Graves' hyperthyroidism: how long should antithyroid drug therapy
282 be continued to achieve remission? *Nat Clin Pract Endocrinol Metab.*
283 2006;2(1):2-3. doi: 10.1038/ncpendmet0068. PubMed PMID: 16932244.
- 284 11. Lippe BM, Landaw EM, Kaplan SA. Hyperthyroidism in children treated with
285 long term medical therapy: twenty-five percent remission every two years. *J Clin*
286 *Endocrinol Metab.* 1987;64(6):1241-5. doi: 10.1210/jcem-64-6-1241. PubMed
287 PMID: 3571426.
- 288 12. Ohye H, Minagawa A, Noh JY, Mukasa K, Kunii Y, Watanabe N, et al.
289 Antithyroid drug treatment for graves' disease in children: a long-term
290 retrospective study at a single institution. *Thyroid.* 2014;24(2):200-7. doi:
291 10.1089/thy.2012.0612. PubMed PMID: 23926918.
- 292 13. Jevalikar G, Solis J, Zacharin M. Long-term outcomes of pediatric Graves' disease.
293 *J Pediatr Endocrinol Metab.* 2014;27(11-12):1131-6. doi:
294 10.1515/jpem-2013-0342. PubMed PMID: 24945422.
- 295 14. Havgaard Kjaer R, Smedegard Andersen M, Hansen D. Increasing Incidence of
296 Juvenile Thyrotoxicosis in Denmark: A Nationwide Study, 1998-2012. *Horm Res*

- 297 Paediatr. 2015;84(2):102-7. doi: 10.1159/000430985. PubMed PMID: 26111962.
- 298 15. Barlow AB, Wheatcroft N, Watson P, Weetman AP. Association of
299 HLA-DQA1*0501 with Graves' disease in English Caucasian men and women.
300 Clin Endocrinol (Oxf). 1996;44(1):73-7. Epub 1996/01/01. PubMed PMID:
301 8706297.
- 302 16. Shulman DI, Muhar I, Jorgensen EV, Diamond FB, Bercu BB, Root AW.
303 Autoimmune hyperthyroidism in prepubertal children and adolescents:
304 comparison of clinical and biochemical features at diagnosis and responses to
305 medical therapy. Thyroid. 1997;7(5):755-60. doi: 10.1089/thy.1997.7.755.
306 PubMed PMID: 9349579.
- 307 17. Lazar L, Kalter-Leibovici O, Pertzalan A, Weintrob N, Josefsberg Z, Phillip M.
308 Thyrotoxicosis in prepubertal children compared with pubertal and postpubertal
309 patients. J Clin Endocrinol Metab. 2000;85(10):3678-82. doi:
310 10.1210/jcem.85.10.6922. PubMed PMID: 11061522.
- 311 18. Leu SW, Chi CS, Shu SG. Outcome of antithyroid medication and radioiodine
312 therapy in pediatric Graves' disease. Acta Paediatr Taiwan. 2003;44(4):220-6.
313 PubMed PMID: 14674226.
- 314 19. Manji N, Carr-Smith JD, Boelaert K, Allahabadia A, Armitage M, Chatterjee VK,
315 et al. Influences of age, gender, smoking, and family history on autoimmune
316 thyroid disease phenotype. J Clin Endocrinol Metab. 2006;91(12):4873-80. doi:
317 10.1210/jc.2006-1402. PubMed PMID: 16968788.
- 318 20. Dauksiene D, Dauksa A, Mickuviene N. Independent pretreatment predictors of
319 Graves' disease outcome. Medicina (Kaunas). 2013;49(10):427-34. PubMed
320 PMID: 24709784.
- 321 21. Gastaldi R, Poggi E, Mussa A, Weber G, Vigone MC, Salerno M, et al. Graves

- 322 disease in children: thyroid-stimulating hormone receptor antibodies as remission
323 markers. *J Pediatr*. 2014;164(5):1189-94 e1. doi: 10.1016/j.jpeds.2013.12.047.
324 PubMed PMID: 24518168.
- 325 22. Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, et al. Clinical features of
326 patients with Graves' disease undergoing remission after antithyroid drug
327 treatment. *Thyroid*. 1997;7(3):369-75. doi: 10.1089/thy.1997.7.369. PubMed
328 PMID: 9226205.
- 329 23. Diana T, Brown RS, Bossowski A, Segni M, Niedziela M, Konig J, et al. Clinical
330 relevance of thyroid-stimulating autoantibodies in pediatric graves' disease-a
331 multicenter study. *J Clin Endocrinol Metab*. 2014;99(5):1648-55. doi:
332 10.1210/jc.2013-4026. PubMed PMID: 24517152.
- 333 24. Shibayama K, Ohyama Y, Yokota Y, Ohtsu S, Takubo N, Matsuura N. Assays for
334 thyroid-stimulating antibodies and thyrotropin-binding inhibitory
335 immunoglobulins in children with Graves' disease. *Endocr J*. 2005;52(5):505-10.
336 PubMed PMID: 16284425.
- 337 25. Abraham P, Avenell A, Park CM, Watson WA, Bevan JS. A systematic review of
338 drug therapy for Graves' hyperthyroidism. *Eur J Endocrinol*. 2005;153(4):489-98.
339 doi: 10.1530/eje.1.01993. PubMed PMID: 16189168.
- 340 26. Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016
341 American Thyroid Association Guidelines for Diagnosis and Management of
342 Hyperthyroidism and Other Causes of Thyrotoxicosis. *Thyroid*.
343 2016;26(10):1343-421. doi: 10.1089/thy.2016.0229. PubMed PMID: 27521067.
- 344 27. Committee on Pharmaceutical Affairs JSfPE, the Pediatric Thyroid Disease
345 Committee JTA, Minamitani K, Sato H, Ohye H, Harada S, et al. Guidelines for
346 the treatment of childhood-onset Graves' disease in Japan, 2016. *Clin Pediatr*

- 347 Endocrinol. 2017;26(2):29-62. doi: 10.1297/cpe.26.29. PubMed PMID: 28458457;
348 PubMed Central PMCID: PMC5402306.
- 349 28. Azizi F, Amouzegar A. Management of thyrotoxicosis in children and adolescents:
350 35 years' experience in 304 patients. J Pediatr Endocrinol Metab.
351 2018;31(2):159-65. doi: 10.1515/jpem-2017-0394. PubMed PMID: 29306930.
- 352 29. Leger J, Carel JC. Hyperthyroidism in childhood: causes, when and how to treat. J
353 Clin Res Pediatr Endocrinol. 2013;5 Suppl 1:50-6. doi: 10.4274/jcrpe.854.
354 PubMed PMID: 23154161; PubMed Central PMCID: PMC5402306.
- 355 30. Kourime M, McGowan S, Al Towati M, Ahmed SF, Stewart G, Williamson S, et
356 al. Long-term outcome of thyrotoxicosis in childhood and adolescence in the west
357 of Scotland: the case for long-term antithyroid treatment and the importance of
358 initial counselling. Arch Dis Child. 2018;103(7):637-42. doi:
359 10.1136/archdischild-2017-313454. PubMed PMID: 29269558; PubMed Central
360 PMCID: PMC6047164.
- 361 31. Cheetham T, Lane L. Graves' disease. Time to move on. Arch Dis Child. 2018.
362 doi: 10.1136/archdischild-2017-314486. PubMed PMID: 29348117




Fig1

bioRxiv preprint first posted online Apr. 25, 2019; doi: <http://dx.doi.org/10.1101/618942>. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).




Fig2